Menin Inhibition With Revumenib for KMT2A-Rearranged Relapsed or Refractory Acute Leukemia (AUGMENT-101).
Ghayas C Issa, Ibrahim Aldoss, Michael J Thirman...
https://pubmed.ncbi.nlm.nih.gov/39121437/Actively Recruiting
Led by Syndax Pharmaceuticals · Updated on 2026-10-09
447
Participants Needed
57
Research Sites
N/A
Total Duration
Researchers are studying revumenib in participants with relapsed or refractory acute leukemias, including those with specific genetic changes like MLLKMT2A gene rearrangement or NPM1 mutation. This Phase 12 trial aims to find the highest safe dose and recommended dose for Phase 2, then evaluate how well revumenib works and how safe it is in different groups of acute leukemia patients. In Phase 1, participants receive oral revumenib in six different groups based on their use of other medications affecting liver enzymes or antifungal treatments. One group also receives cobicistat daily along with revumenib. Phase 2 includes four specific groups of participants with different types of acute leukemia or genetic mutations, all receiving revumenib to assess its effects and safety over time. Participants will be closely monitored throughout the study with blood tests, physical exams, and assessments to track side effects and measure how the leukemia responds to treatment. The study measures include dose-limiting toxicities, adverse events, drug levels in the blood, and leukemia response rates. This careful monitoring continues for up to several years to understand the long-term effects and safety of revumenib.
CONDITIONS
A Study of Revumenib in R/R Leukemias Including Those With an MLL/KMT2A Gene Rearrangement or NPM1 Mutation
S
Syndax Pharmaceuticals
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Syndax Pharmaceuticals
Lead Sponsor
This table compares participation in this trial with other options available for this condition. The information is drawn from published research and the trial’s study details and is provided for educational purposes only.
| Factors | Revumenib (menin inhibitor) treatment | Current‑care salvage therapies |
|---|---|---|
| What it is | An investigational oral menin inhibitor regimen (revumenib) administered in sequential cohorts, including combinations with cobicistat or CYP3A4 inhibitors to manage drug interactions. | Standard salvage options for relapsed/refractory acute leukemia include intensive re‑induction chemotherapy or lower‑intensity regimens such as hypomethylating agents plus venetoclax. |
| Role in the trial | Assigned intervention evaluated in multiple sequential cohorts to assess safety, dosing, and activity in relapsed/refractory leukemia. | Not part of trial; serves as external clinical context based on standard practice. |
| Primary use | Treatment of relapsed or refractory acute leukemia, particularly KMT2A‑rearranged or NPM1‑mutated cases. | Used as salvage therapy to induce remission or bridge patients with relapsed/refractory disease to transplant or further therapy. |
| How it is given or performed | Given orally in cohorts that vary by co‑administration with CYP3A4 inhibitors or cobicistat to manage pharmacokinetic interactions. | Intensive chemotherapy is typically intravenous; hypomethylating agents plus venetoclax are given via injection or orally on defined schedules. |
| Evidence status | Clinical activity being evaluated; outcomes such as remission rates, pharmacokinetics, and toxicity under investigation. | Established efficacy from retrospective series and clinical experience, though long‑term outcomes remain poor for R/R patients. |
| Important risks | Potential differentiation syndrome, QTc prolongation, cytopenias; risk profiles being characterized across cohorts. | Risks include cytopenias, organ toxicity, treatment‑related mortality or morbidity with intensive regimens. |
| Important limitations | Results are preliminary; sequential cohort design limits cross‑cohort comparison; no comparator arm in the trial itself. | Historically low long‑term survival rates and poor durability of response in relapsed/refractory acute leukemia. |
Disclaimer: This comparison is created with the help of artificial intelligence(AI) and may contain errors or missing information. It is not medical advice and does not mean one option is better or safer than another. Clinical trials are still being studied, and joining a trial is your choice. Please consult your healthcare professional before making any decisions.
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are assessed for eligibility based on medical history, lab tests, and current health status.
1 to 2 visits
Duration - Approximately 1 year
Participants receive oral revumenib at increasing doses in one of six groups depending on other medications they take, including some receiving cobicistat. This phase identifies the safest dose levels.
Regular visits for monitoring and assessments
Duration - Up to 3 years
Participants with specific types of acute leukemia receive the recommended dose of revumenib to evaluate safety, tolerability, and effectiveness in different leukemia subgroups.
Frequent visits for safety and response evaluations
Duration - Up to 5 years
Participants are monitored over several years to assess long-term safety, leukemia response, and survival outcomes.
Periodic follow-up visits
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SEQUENTIAL
Primary Purpose
TREATMENT
Number of Arms
1
Have more questions? Get in touch with our team for quick support
Ghayas C Issa, Ibrahim Aldoss, Michael J Thirman...
https://pubmed.ncbi.nlm.nih.gov/39121437/Daniel Sasca, Borhane Guezguez, Michael W M Kühn
https://pubmed.ncbi.nlm.nih.gov/34267079/Miriam B Garcia, Bofei Wang, Irtiza Sheikh...
https://pubmed.ncbi.nlm.nih.gov/41621809/Ghayas C Issa, Ibrahim Aldoss, John DiPersio...
https://pubmed.ncbi.nlm.nih.gov/36922593/Martha L Arellano, Michael J Thirman, John F DiPersio...
https://pubmed.ncbi.nlm.nih.gov/40332046/Jennifer A Jiménez, April A Apfelbaum, Allegra G Hawkins...
https://pubmed.ncbi.nlm.nih.gov/33741715/Syndax Pharmaceuticals
Lead Sponsor